“Jazz Pharmaceuticals Plc (JAZZ $59 Nasdaq) — Based in Dublin, Ireland, this specialty biopharmaceutical company offers earnings estimated at 27% a year and a P/E of 9 for a rock-bottom PEG ratio of 0.33. Now at 58, Cantor Fitzgerald upped its target price to 86. Strong Buy. Estimated Target Price: 75. Suggested Loss Limit: 54.70.”
- Stephen Quickel, US Investment Report, March 15, 2013